Table 3 Univariate and multivariable analysis of overall survival (n = 73)
From: Fractionated stereotactic radiotherapy of brain metastases: results of a retrospective study
Univariate model | Multivariate model | |||||
|---|---|---|---|---|---|---|
Characteristics | HR | 95%CI | P - value | HR | 95%CI | P - value |
Gross tumor volume (cm³) | ||||||
≤ 1.5cm³ (reference) | ||||||
> 1.5cm³ | 2.301 | 1.233, 4.294 | 0.009 | 3.620 | 1.413, 9.273 | 0.007 |
Extracranial metastases | ||||||
No (reference) | ||||||
Yes | 3.627 | 1.659, 7.933 | 0.001 | 0.908 | 0.209, 3.946 | 0.898 |
Control of primary cancer | ||||||
Control (reference) | ||||||
No control | 1.385 | 0.608, 3.157 | 0.438 | 1.330 | 0.526, 3.360 | 0.547 |
Systemic treatment * 3 months before/after FSRT | ||||||
Yes (reference) | ||||||
No | 1.632 | 0.633, 4.208 | 0.310 | 1.779 | 0.450, 7.029 | 0.412 |
Karnofsky performance score (KPS) | 0.949 | 0.924, 0.975 | < 0.001 | 0.941 | 0.889, 0.996 | 0.034 |
Number of brain metastases | 1.121 | 0.832, 1.509 | 0.453 | 1.091 | 0.655, 1.819 | 0.737 |
Patient age | 1.012 | 0.988, 1.037 | 0.334 | 0.967 | 0.920, 1.016 | 0.187 |
Recursive partitioning analysis (RPA) | 2.506 | 1.550, 4.051 | < 0.001 | 0.691 | 0.249, 1.921 | 0.479 |
Diagnosis-specific graded prognostic assessment (ds-GPA) | 0.479 | 0.328, 0.700 | < 0.001 | 0.543 | 0.155, 1.910 | 0.341 |
Histology | ||||||
Malignant melanoma/renal cell cancer (reference) | ||||||
Other | 1.127 | 0.608, 2.089 | 0.704 | 0.482 | 0.200, 1.160 | 0.103 |
Cerebral progression outside the planning target volume | ||||||
No (reference) | ||||||
Yes | 1.356 | 0.708, 2.594 | 0.358 | 1.574 | 0.692, 3.582 | 0.279 |